Skip to main content
. 2020 Apr 20;117(17):9644–9645. doi: 10.1073/pnas.2005945117

Fig. 2.

Fig. 2.

Inhibition of PRMT5 sensitizes melanoma cells to palbociclib. (A) Western blot on melanoma cell lysates after 6-d treatment with 2 μM palbociclib. (B) Western blot on melanoma cell lysates after 6-d treatment with 500 nM GSK3326595 for all cells except HT144, which were treated with 250 nM. (C and D) Proliferation curves of the parental and acquired resistance (AR) cells treated with 2 μM palbociclib, 250 nM (HT144), or 500 nM (A375) GSK3326595, or combination of both drugs. Graphs are representative of three independent experiments. Error bars represent SEM for 3 technical replicates. (E) Images of colony-forming assays of A375AR and HT1441AR cells treated as in C and D for 14 d, and after drug removal for 14 d. Representative of 2 biological replicates with 3 technical replicates each. (F and G) Proliferation curves of the parental A375 and HT144 cells treated with 1 μM (A375) or 250 nM (HT144) palbociclib, 500 nM (A375) or 250 nM (HT144) GSK3326595, or combination of both drugs. Graphs are representative of two independent experiments. Error bars represent SEM for 3 technical replicates. (H) Images of colony-forming assays of A375 treated as in F and G, and after drug removal for 14 d. Representative of 2 biological replicates with 3 technical replicates each.